Fig. 4.

The serum levels of interleukin (IL)-6 from rheumatoid arthritis (RA) patients with or without acute-phase serum amyloid (SAA) normalization. RA patients receiving tofacitinib were divided into patients with an adequate decline in SAA (normalization; <8 μg/ml) and patients with an inadequate SAA decline (without normalization, ≥8 μg/ml) at 4 weeks. SAA was measured before and at 4 weeks after tofacitinib treatment in both patient groups. There was a significant difference between the IL-6 levels before and at 4 weeks in the patients with SAA normalization.